{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:22:53Z","timestamp":1707524573505},"reference-count":43,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,6]]},"DOI":"10.7759\/cureus.26619","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T03:52:23Z","timestamp":1657165943000},"source":"Crossref","is-referenced-by-count":0,"title":["Trametinib: Could It Be a Promising Drug to Treat Atypical Chronic Myeloid Leukemia?"],"prefix":"10.7759","author":[{"given":"Marwa","family":"Elsayed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Harry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suprana","family":"Nanua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shayaan","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad H","family":"Habib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahzad","family":"Raza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-500959","article-title":"The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment","volume":"122","author":"Gotlib J","year":"2013","unstructured":"Gotlib J, Maxson JE, George TI, Tyner JW. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood. 2013, 122:1707-11. 10.1182\/blood-2013-05-500959","journal-title":"Blood"},{"key":"ref2","article-title":"Identification of risk factors in atypical chronic myeloid leukemia","volume":"91","author":"Breccia M","year":"2006","unstructured":"Breccia M, Biondo F, Latagliata R, Carmosino I, Mandelli F, Alimena G. Identification of risk factors in atypical chronic myeloid leukemia. Haematologica. 2006, 91:1566-8.","journal-title":"Haematologica"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-016-0350-1","article-title":"An exercise in extrapolation: clinical management of atypical CML, MDS\/MPN-unclassifiable, and MDS\/MPN-RS-T","volume":"11","author":"Talati C","year":"2016","unstructured":"Talati C, Padron E. An exercise in extrapolation: clinical management of atypical CML, MDS\/MPN-unclassifiable, and MDS\/MPN-RS-T. Curr Hematol Malig Rep. 2016, 11:425-33. 10.1007\/s11899-016-0350-1","journal-title":"Curr Hematol Malig Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang SA","year":"2014","unstructured":"Wang SA, Hasserjian RP, Fox PS, et al.. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms. Blood. 2014, 123:2645-51. 10.1182\/blood-2014-02-553800","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10832","article-title":"Characteristics and outcome of patients with Philadelphia chromosome negative, bcr\/abl negative chronic myelogenous leukemia","volume":"95","author":"Onida F","year":"2002","unstructured":"Onida F, Ball G, Kantarjian HM, et al.. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr\/abl negative chronic myelogenous leukemia. Cancer. 2002, 95:1673-84. 10.1002\/cncr.10832","journal-title":"Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24722","article-title":"Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia","volume":"92","author":"Patnaik MM","year":"2017","unstructured":"Patnaik MM, Barraco D, Lasho TL, et al.. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol. 2017, 92:542-8. 10.1002\/ajh.24722","journal-title":"Am J Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-62146-3_11","article-title":"Atypical chronic myeloid leukemia, BCR\/ABL1 negative","author":"Levinson KB","year":"2018","unstructured":"Levinson KB, Bagg A. Atypical chronic myeloid leukemia, BCR\/ABL1 negative. Precision Molecular Pathology of Myeloid Neoplasms. Chang CC, Ohgami R (ed): Springer, Cham, Switzerland; 2018. 10.1007\/978-3-319-62146-3_11"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5114%2Fwo.2018.74388","article-title":"Atypical chronic myeloid leukaemia - a rare subtype of myelodysplastic\/myeloproliferative neoplasm","volume":"22","author":"Drozd-Soko\u0142owska JE","year":"2018","unstructured":"Drozd-Soko\u0142owska JE, Waszczuk-Gajda A, M\u0105dry K, Dwilewicz-Trojaczek J. Atypical chronic myeloid leukaemia - a rare subtype of myelodysplastic\/myeloproliferative neoplasm. Contemp Oncol. 2018, 22:14-9. 10.5114%2Fwo.2018.74388","journal-title":"Contemp Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2019.101133","article-title":"Atypical CML- the role of morphology and precision genomics","volume":"33","author":"Lasho T","year":"2020","unstructured":"Lasho T. Atypical CML- the role of morphology and precision genomics. Best Pract Res Clin Haematol. 2020, 33:101133. 10.1016\/j.beha.2019.101133","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref10","article-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe ES","year":"2001","unstructured":"Jaffe ES. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France; 2001."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber DA","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al.. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016, 127:2391-405. 10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman JW","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, et al.. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009, 114:937-51. 10.1182\/blood-2009-03-209262","journal-title":"Blood"},{"key":"ref13","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France; 2008."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2015.1.264","article-title":"What's different about atypical CML and chronic neutrophilic leukemia?","volume":"2015","author":"Dao KH","year":"2015","unstructured":"Dao KH, Tyner JW. What's different about atypical CML and chronic neutrophilic leukemia?. Hematology Am Soc Hematol Educ Program. 2015, 2015:264-71. 10.1182\/asheducation-2015.1.264","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-47913-4.00017-3","article-title":"Myeloproliferative and \u201coverlap\u201d myelodysplastic\/myeloproliferative neoplasms","author":"Thakral B","year":"2018","unstructured":"Thakral B, Anastasi J, Wang SA. Myeloproliferative and \u201coverlap\u201d myelodysplastic\/myeloproliferative neoplasms. Hematopathology. Elsevier, Amsterdam, Netherlands; 2018. 488-538. 10.1016\/B978-0-323-47913-4.00017-3"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza R","year":"2013","unstructured":"Piazza R, Valletta S, Winkelmann N, et al.. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013, 45:18-24. 10.1038\/ng.2495","journal-title":"Nat Genet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia","volume":"125","author":"Gambacorti-Passerini CB","year":"2015","unstructured":"Gambacorti-Passerini CB, Donadoni C, Parmiani A, et al.. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood. 2015, 125:499-503. 10.1182\/blood-2014-06-579466","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer M","year":"2013","unstructured":"Meggendorfer M, Bacher U, Alpermann T, et al.. SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia. 2013, 27:1852-60. 10.1038\/leu.2013.133","journal-title":"Leukemia"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.35","article-title":"SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias","volume":"27","author":"Damm F","year":"2013","unstructured":"Damm F, Itzykson R, Kosmider O, et al.. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia. 2013, 27:1401-3. 10.1038\/leu.2013.35","journal-title":"Leukemia"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0774-4","article-title":"Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia","volume":"17","author":"Rocca S","year":"2018","unstructured":"Rocca S, Carr\u00e0 G, Poggio P, Morotti A, Brancaccio M. Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia. Mol Cancer. 2018, 17:40. 10.1186\/s12943-018-0774-4","journal-title":"Mol Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0334","article-title":"Atypical chronic myeloid leukemia: a rare entity with management challenges","volume":"14","author":"Dhakal P","year":"2018","unstructured":"Dhakal P, Gundabolu K, Amador C, Rayamajhi S, Bhatt VR. Atypical chronic myeloid leukemia: a rare entity with management challenges. Future Oncol. 2018, 14:177-85. 10.2217\/fon-2017-0334","journal-title":"Future Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704472","article-title":"Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative\/BCR-ABL-negative chronic myelogenous leukemia","volume":"33","author":"Mittal P","year":"2004","unstructured":"Mittal P, Saliba RM, Giralt SA, et al.. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative\/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant. 2004, 33:1005-9. 10.1038\/sj.bmt.1704472","journal-title":"Bone Marrow Transplant"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704686","article-title":"Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia","volume":"34","author":"Koldehoff M","year":"2004","unstructured":"Koldehoff M, Beelen DW, Trenschel R, et al.. Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia. Bone Marrow Transplant. 2004, 34:1047-50. 10.1038\/sj.bmt.1704686","journal-title":"Bone Marrow Transplant"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-693630","article-title":"How I treat atypical chronic myeloid leukemia","volume":"129","author":"Gotlib J","year":"2017","unstructured":"Gotlib J. How I treat atypical chronic myeloid leukemia. Blood. 2017, 129:838-45. 10.1182\/blood-2016-08-693630","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.11.2915","article-title":"BCR rearrangement-negative chronic myelogenous leukemia revisited","volume":"19","author":"Kurzrock R","year":"2001","unstructured":"Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al.. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol. 2001, 19:2915-26. 10.1200\/JCO.2001.19.11.2915","journal-title":"J Clin Oncol"},{"key":"ref26","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V78.1.205.205","article-title":"Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique","volume":"78","author":"Martiat P","year":"1991","unstructured":"Martiat P, Michaux JL, Rodhain J. Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique. Blood. 1991, 78:205-11.","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23018","article-title":"PEG-IFN-\u03b1-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study","volume":"110","author":"Jabbour E","year":"2007","unstructured":"Jabbour E, Kantarjian H, Cortes J, et al.. PEG-IFN-\u03b1-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer. 2007, 110:2012-8. 10.1002\/cncr.23018","journal-title":"Cancer"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24396","article-title":"Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management","volume":"91","author":"Patnaik MM","year":"2016","unstructured":"Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management. Am J Hematol. 2016, 91:631-42. 10.1002\/ajh.24396","journal-title":"Am J Hematol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11543","article-title":"Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia","volume":"98","author":"Kantarjian HM","year":"2003","unstructured":"Kantarjian HM, O'Brien S, Cortes J, et al.. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 2003, 98:522-8. 10.1002\/cncr.11543","journal-title":"Cancer"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215605662","article-title":"Activity of single-agent decitabine in atypical chronic myeloid leukemia","volume":"22","author":"Hausmann H","year":"2016","unstructured":"Hausmann H, Bhatt VR, Yuan J, Maness LJ, Ganti AK. Activity of single-agent decitabine in atypical chronic myeloid leukemia. J Oncol Pharm Pract. 2016, 22:790-4. 10.1177\/1078155215605662","journal-title":"J Oncol Pharm Pract"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.4172\/2167-7700.1000114","article-title":"The first case of decitabine successfully in treatment of atypical chronic myeloid leukemia with CEBPA double mutation","volume":"2","author":"Mao L","year":"2013","unstructured":"Mao L, You L, Yang M, Li Y, Ye X, Tong H. The first case of decitabine successfully in treatment of atypical chronic myeloid leukemia with CEBPA double mutation. Chemotherapy. 2013, 2:114. 10.4172\/2167-7700.1000114","journal-title":"Chemotherapy"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.986477","article-title":"Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia","volume":"56","author":"Tong X","year":"2015","unstructured":"Tong X, Li J, Zhou Z, Zheng D, Liu J, Su C. Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia. Leuk Lymphoma. 2015, 56:1911-3. 10.3109\/10428194.2014.986477","journal-title":"Leuk Lymphoma"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3977","article-title":"Decitabine for the treatment of atypical chronic myeloid leukemia: a report of two cases","volume":"11","author":"Jiang H","year":"2016","unstructured":"Jiang H, Wu Z, Ren LI, Tao D, Tong H. Decitabine for the treatment of atypical chronic myeloid leukemia: a report of two cases. Oncol Lett. 2016, 11:689-92. 10.3892\/ol.2015.3977","journal-title":"Oncol Lett"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186862","article-title":"Atypical chronic myeloid leukemia: where are we now?","volume":"21","author":"Cris\u00e0 E","year":"2020","unstructured":"Cris\u00e0 E, Nicolosi M, Ferri V, Favini C, Gaidano G, Patriarca A. Atypical chronic myeloid leukemia: where are we now?. Int J Mol Sci. 2020, 21:6862. 10.3390\/ijms21186862","journal-title":"Int J Mol Sci"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison C","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, et al.. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012, 366:787-98. 10.1056\/NEJMoa1110556","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi AM","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, et al.. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015, 372:426-35. 10.1056\/NEJMoa1409002","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24972","article-title":"A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms","volume":"93","author":"Assi R","year":"2018","unstructured":"Assi R, Kantarjian HM, Garcia-Manero G, et al.. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms. Am J Hematol. 2018, 93:277-85. 10.1002\/ajh.24972","journal-title":"Am J Hematol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson JE","year":"2013","unstructured":"Maxson JE, Gotlib J, Pollyea DA, et al.. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013, 368:1781-90. 10.1056\/NEJMoa1214514","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2020.100208","article-title":"CSF3R truncation mutations in a patient with B-cell acute lymphoblastic leukemia and a favorable response to chemotherapy plus dasatinib","volume":"14","author":"Schwartz MS","year":"2020","unstructured":"Schwartz MS, Wieduwilt MJ. CSF3R truncation mutations in a patient with B-cell acute lymphoblastic leukemia and a favorable response to chemotherapy plus dasatinib. Leuk Res Rep. 2020, 14:100208. 10.1016\/j.lrr.2020.100208","journal-title":"Leuk Res Rep"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-574582","article-title":"Preclinical efficacy of MEK inhibition in Nras-mutant AML","volume":"124","author":"Burgess MR","year":"2014","unstructured":"Burgess MR, Hwang E, Firestone AJ, et al.. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood. 2014, 124:3947-55. 10.1182\/blood-2014-05-574582","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29986","article-title":"Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies","volume":"122","author":"Borthakur G","year":"2016","unstructured":"Borthakur G, Popplewell L, Boyiadzis M, et al.. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016, 122:1871-9. 10.1002\/cncr.29986","journal-title":"Cancer"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22283","article-title":"MEK\/ERK addiction in CNL\/aCML","volume":"8","author":"Kesarwani M","year":"2017","unstructured":"Kesarwani M, Kincaid Z, Azam M. MEK\/ERK addiction in CNL\/aCML. Oncotarget. 2017, 8:99215-6. 10.18632\/oncotarget.22283","journal-title":"Oncotarget"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.414","article-title":"Durable disease control with MEK inhibition in a patient with NRAS-mutated atypical chronic myeloid leukemia","volume":"7","author":"Khanna V","year":"2015","unstructured":"Khanna V, Pierce ST, Dao KH, et al.. Durable disease control with MEK inhibition in a patient with NRAS-mutated atypical chronic myeloid leukemia. Cureus. 2015, 7:e414. 10.7759\/cureus.414","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/99290-trametinib-could-it-be-a-promising-drug-to-treat-atypical-chronic-myeloid-leukemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:39:43Z","timestamp":1707507583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/99290-trametinib-could-it-be-a-promising-drug-to-treat-atypical-chronic-myeloid-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":43,"URL":"https:\/\/doi.org\/10.7759\/cureus.26619","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,6]]}}}